The need for a strategic therapeutic approach: multiple sclerosis in check

被引:22
作者
Inojosa, Hernan [1 ]
Proschmann, Undine [1 ]
Akguen, Katja [1 ]
Ziemssen, Tjalf [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Ctr Clin Neurosci, Dept Neurol, Fetscherstr 74, D-01307 Dresden, Germany
关键词
disease-modifying therapies; DMTs; multiple sclerosis; strategy; treatment; chess; INTRAMUSCULAR INTERFERON BETA-1A; LONG-TERM OUTCOMES; DISEASE-ACTIVITY; NO EVIDENCE; CONVERSION; TIME; NEUROLOGISTS; ASSOCIATION; DISABILITY; EVOLUTION;
D O I
10.1177/20406223211063032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is the most common chronic autoimmune neurological disease. Its therapeutic management has drastically evolved in the recent years with the development of specific disease-modifying therapies (DMTs). Together with the established injectables, oral and intravenous alternatives are now available for MS patients with significant benefits to modulate the disease course. Certain drugs present with a higher efficacy than the others, profiles and frequencies of adverse events differentiate as well. Thus due to the several and different treatment alternatives, the therapeutic approach adopted by neurologists requires a tactical focus for a targeted, timed, and meaningful treatment decision. An integration of rational and emotional control with proper communication skills is necessary for shared decision-making with patients. In this perspective paper, we reinforce the necessary concept of strategic MS treatment approach using all available therapies based on scientific evidence and current experience. We apply a didactic analogy to the strategic game chess. The opening with oriented attack (i.e. already in early disease stages as clinical isolated syndrome), a correct choice of chess pieces to move (i.e. among the several DMTs), a re-assessment reaction to different scenarios (e.g. sustained disease activity, adverse events, and family planning) and the advantage of real-world data are discussed to try the best approach to ultimately successfully approach the best personalized MS treatment.
引用
收藏
页数:15
相关论文
共 74 条
  • [1] Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis
    Armoiry, X.
    Kan, A.
    Melendez-Torres, G. J.
    Court, R.
    Sutcliffe, P.
    Auguste, P.
    Madan, J.
    Counsell, C.
    Clarke, A.
    [J]. JOURNAL OF NEUROLOGY, 2018, 265 (05) : 999 - 1009
  • [2] Interferon β-1a for early multiple sclerosis:: CHAMPS trial subgroup analyses
    Beck, RW
    Chandler, DL
    Cole, SR
    Simon, JH
    Jacobs, LD
    Kinkel, RP
    Selhorst, JB
    Rose, JW
    Cooper, JA
    Rice, G
    Murray, TJ
    Sandrock, AW
    [J]. ANNALS OF NEUROLOGY, 2002, 51 (04) : 481 - 490
  • [3] Neurologists The Last Bedside Physician-Scientists
    Berger, Joseph R.
    [J]. JAMA NEUROLOGY, 2013, 70 (08) : 965 - 966
  • [4] Treatment of Acute Relapses in Multiple Sclerosis
    Berkovich, Regina
    [J]. NEUROTHERAPEUTICS, 2013, 10 (01) : 97 - 105
  • [5] Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
    Brown, J. William L.
    Coles, Alasdair
    Horakova, Dana
    Havrdova, Eva
    Izquierdo, Guillermo
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Trojano, Maria
    Lugaresi, Alessandra
    Bergamaschi, Roberto
    Grammond, Pierre
    Alroughani, Raed
    Hupperts, Raymond
    McCombe, Pamela
    Van Pesch, Vincent
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Lechner-Scott, Jeannette
    Flechter, Schlomo
    Slee, Mark
    Shaygannejad, Vahid
    Pucci, Eugenio
    Granella, Franco
    Jokubaitis, Vilija
    Willis, Mark
    Rice, Claire
    Scolding, Neil
    Wilkins, Alastair
    Pearson, Owen R.
    Ziemssen, Tjalf
    Hutchinson, Michael
    Harding, Katharine
    Jones, Joanne
    McGuigan, Christopher
    Butzkueven, Helmut
    Kalincik, Tomas
    Robertson, Neil
    Onofrj, Marco
    De Luca, Giovanna
    Di Tommaso, Valeria
    Travaglini, Daniela
    Pietrolongo, Erika
    di Ioia, Maria
    Farina, Deborah
    Mancinelli, Luca
    Hodgkinson, Suzanne
    Oreja-Guevara, Celia
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (02): : 175 - 187
  • [6] Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis
    Brownlee, Wallace J.
    Altmann, Dan R.
    Prados, Ferran
    Miszkiel, Katherine A.
    Eshaghi, Arman
    Wheeler-Kingshott, Claudia A. M. Gandini
    Barkhof, Frederik
    Ciccarelli, Olga
    [J]. BRAIN, 2019, 142 : 2276 - 2287
  • [7] Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS
    Capra, Ruggero
    Cordioli, Cinzia
    Rasia, Sarah
    Gallo, Fabio
    Signori, Alessio
    Sormani, Maria Pia
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : 1757 - 1761
  • [8] Chataway Jeremy, 2018, Lancet Neurol, V17, P118, DOI 10.1016/S1474-4422(17)30463-5
  • [9] Corticosteroids for the long-term treatment in multiple sclerosis
    Ciccone, A.
    Beretta, S.
    Brusaferri, F.
    Galea, I
    Protti, A.
    Spreafico, C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [10] The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
    Claflin, Suzi B.
    Broadley, Simon
    Taylor, Bruce V.
    [J]. FRONTIERS IN NEUROLOGY, 2019, 9